Nanotechnology Now - Press Release: ULURU Inc. Presents Nanoparticle Wound Care Technology at the Society for Biomaterials 2007 Annual Meeting and Exposition

Home > Press > ULURU Inc. Presents Nanoparticle Wound Care Technology at the Society for Biomaterials 2007 Annual Meeting and Exposition

Abstract:
- Data Indicate Potential to Significantly Accelerate Wound Healing -
- Technology for Controlled Release of Actives into Wounds -

ULURU Inc. Presents Nanoparticle Wound Care Technology at the Society for Biomaterials 2007 Annual Meeting and Exposition

ADDISON, TX | Posted on April 23rd, 2007

ULURU Inc. (OTC
Bulletin Board: ULUR) announced that its nanoparticle aggregate technology
was presented today at the Society for Biomaterials 2007 Annual Meeting and
Exposition. This presentation was given by Dr. John St. John, Vice
President of Material Science, a co-inventor of the technology, during the
Regenerative Medicine and Clinical Translation II (wound healing) session
of the meeting.

The presentation titled "Immediate Shape-Retentive Wound Dressings
Formed In Situ Using Hydrogel Nanoparticle Powders" is the first scientific
presentation of this exciting new technology. The presentation initially
focused on the methods for the synthesis, purification and the physical
properties of the material. Wound healing data, in porcine full-thickness
wounds and skin graft donor site models, also presented demonstrating the
superiority of the nanoparticle aggregate dressing, compared with a leading
commercial product, to accelerate wound healing.

Results presented by Dr. St. John demonstrated the ability to control
the release of drugs and proteins from the nanoparticle dressing for a
period of time in excess of 30 days. This unique property of the
nanoparticle aggregate wound dressing offers the exciting opportunity of
controlling the release of growth factors and other actives to accelerate
wound healing.

A summary of the attributes of the nanoparticle aggregate technology
included:

* Forms a film in situ sealing the wound and allowing conformation to
irregular wound surfaces
* Adheres to the wound but does not harm the healing tissue
* The dressing is moisture vapor and oxygen permeable
* Substantially decreases the need for multiple dressing changes
* Active healing agents can be trapped between the nanoparticles to
control the release of these actives to promote wound healing

Commenting on this presentation Dr. Spencer A. Brown, Director of
Research, Plastic Surgery Department University of Texas Southwestern
Medical center of Dallas, a co-author of the paper, stated, "At the
University of Texas Southwestern Medical Center we have extensively
evaluated this material both as a non-medicated dressing and an advanced
wound dressing incorporating a variety of actives including numerous growth
factors. The results achieved to date are very impressive in all the model
systems we have evaluated. We believe that this material offers great
promise to significantly advance the treatment of wounds and not only
accelerate the wound healing process but also reduce the nursing burden and
cost of patient care."

####

About ULURU Inc.
ULURU Inc. is an emerging specialty pharmaceutical company focused on
the development of a portfolio of wound management, plastic surgery and
oral care products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative transmucosal
delivery system and Hydrogel Nanoparticle Aggregate technology. For further
information about ULURU Inc., please visit our website at
http://www.uluruinc.com .

This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, including but not limited to statements made relating to the
projected benefits of the nanoparticle aggregate dressing and the promise
for improving wound healing. These statements are subject to numerous risks
and uncertainties, including but not limited to the risk factors detailed
in the Company's Annual Report on Form 10-KSB for the year ended December
31, 2006 and other reports filed by us with the Securities and Exchange
Commission.